Analysis: Part D is main cause of $500B Medicare slowdown

Laura Pedulli | | Health Exec | Policy & Regulations

Prescription drug spending (or Part D) has accounted for more than 60 percent of the slowdown in Medicare benefits since 2011, according to an analysis presented in Health Affairs.

Unfortunately, “the outsized role that Part D has played in the Medicare slowdown is bad budget news because it may prove fleeting,” according to authors Loren Adler, research director for the Committee for a Responsible Federal Budget (CRFB) and Adam Rosenberg, policy analyst at CRFB.

Read more below:

The $500 Billion Medicare Slowdown: A Story About Part D

Laura Pedulli

Related Content

$49B in medical debt to be erased from credit reports
$3.3B merger of UnitedHealth and Amedisys delayed by DOJ lawsuit
FDA to hopeful marketers of AI-equipped medical devices: Think beyond your initial approval
FDA issues proposed guidance for improving reliability of pulse oximeters
Bill to regulate healthcare private equity lands on desk of Mass. governor
The biggest obstacles facing radiology business managers in 2025

Around the web

Cardiovascular Business
Stryker acquires Inari Medical for $4.9B

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year.